SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us

    Archive:
    News and Articles on Biotechnology

    Latest News: Biotechnology

    Prince Georges identifies sites for new biotech cluster  Nov 13, 2009
    The consultants recommended eventually building a new biotechnology park on a 250-acre Beltsville plot partly owned by and the. Most Read Stories. (Washington Business Journal, DC)

    Nano Bubble Gum For Enhancing Drug Delivery In Gut  Nov 13, 2009
    Working with a Bay-area biotechnology company, she is making devices that are sort of like spiny beads filled with drugs. The spines on these beads are silicon nanowires designed to form an adhesive interface with the tiny, hair-like cilia that cover the cells lining the gut. (Science Daily)

    You want pesticides with that? Why less means more  Nov 13, 2009
    Search brisbanetimes. You want pesticides with that. (Sydney Morning Herald -- Opinion)

    Australia pledges $70 million for research projects in India  Nov 13, 2009
    The fund is already supporting 50 projects cutting across scientific disciplines, including astronomy, climate change and evolution, malaria vaccines, the impact of global warming on agriculture, water management, computing and biotechnology. Energy cooperation has become an important area of cooperation between the two countries. (India Times, India)

    San Joaquin Valley receives $2m grant for training  Nov 13, 2009
    A $2 million state grant will help train people in the San Joaquin Valley to work in water technology, renewable energy, food processing, agriculture technology and biotechnology -- industries closely tied to the region's farming economy. The grant comes from the California Labor and Workforce Development Agency and goes to the California Partnership for the San Joaquin Valley. (Fresno Bee)

    Mouse cloned to cure Parkinson's  Nov 13, 2009
    The embryonic "stem cells", reports the journal Nature Biotechnology, were grown into new tissue which was implanted into the mouse brain. However, many obstacles stand in the way of human treatments, say experts. (Yahoo News -- Parkinson's Disease)

    Five-step check for nano safety  Nov 13, 2009
    The group of experts says that if the global research community can take advantage of the safety infrastructure already in place for biotechnology and computing, then nanotechnology has a rosy future. But Dr Maynard, from the Woodrow Wilson International Center for Scholars in Washington DC, and colleagues say that the way science is carried out means it is ill-equipped to address novel risks from emerging technologies. (Yahoo News -- Nanotechnology)

    Rising market tide fails to lift some Mass. firms  Nov 13, 2009
    Biotechnology stocks often swim against the market s tide ... But this year most biotech stocks have been big winners, with the leading Amex Biotechnology stock index up 64. (Boston Globe)

    * Universal Vision inks deal with university in Fujian  Nov 13, 2009
    Universal Vision Biotechnology Co (j), Taiwans first biotech firm to list its shares on the GRETAI Securities Market, yesterday signed a pact with a medical university in Fujian Province, paving the way for expansion into China. This partnership will help us train the necessary human resources, letting us get ready to move into the mainland market, chairman Ou Shu-fong (Q) said on the sidelines of the signing ceremony. (Taipei Times, Taiwan -- World)

    SPECIAL REPORT: Welcome to the Clone Farm  Nov 13, 2009
    Still, ViaGen and the Biotechnology Industry Organization have helped to create a supply chain management program to track clones from birth to death. ViaGen also gives farmers the incentive to disclose when and where they cull a clone by holding a deposit until the clone's owner can verify that the animal has been euthanized or slaughtered for meat. (The Star Online, Malaysia)

    Sweet Solution To Energy Production  Nov 13, 2009
    18, 2007) A new analysis has concluded that use of existing biotechnology in the production of so-called bulk chemicals could reduce consumption of non-renewable energy and carbon emissions by 100 percent. (July 25, 2008) Converting livestock manure into a domestic renewable fuel source could generate enough electricity to meet up to three percent of North America's entire consumption needs and lead to a significant. (Science Daily)

    CombiMatrix Corporation Reports Third Quarter 2009 Financial Results  Nov 12, 2009
    CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays... (Primezone Releases)

    Threshold Pharmaceuticals 3Q loss widens on costs  Nov 12, 2009
    Threshold Pharmaceuticals Inc., a development-stage biotechnology company, said late Thursday its third-quarter loss widened on higher research, development, and interest expenses. The company lost $6. (Yahoo News -- Pharmaceutical Industry News)

    J&J to slash 7,000 to 8,000 jobs  Nov 12, 2009
    In May, Jed to buy cancer drug developer Cougar Biotechnology for 970 million in cash. Like rival drugmakers, Jtruggling to refill its pipeline with new drugs to offset sales lost to generic competition and flagging revenue from older products, including some dogged by safety concerns. (Yahoo News -- Pharmaceutical Industry News)

    7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic  Nov 12, 2009
    In May and June, the UK's leading biomedical and animal health research funders the Medical Research Council (MRC), Wellcome Trust and Biotechnology and Biological Sciences Research Council (BBSRC) together with the Department of Health and the Department for Environment, Food and Rural Affairs (Defra), brought together leading clinical and veterinary researchers to catalyse action and a coordinated response from the research community. Today, the outcome of those meetings is announced: a... (EurekAlert! -- Business News)

    Nigeria: Why GM Foods Are Yet to Enter Market - Nabda Boss  Nov 12, 2009
    The major reason behind the delay and circulation of Genetically Modified foods item into the Nigerian market is due to the lack of Biosafety Law in the country, the Director General of the National Biotechnology Development Agency (NABDA) has said ... He said as soon as the Bill is passed into Law the country will start reaping the benefits of the Biotechnology products especially the GMs ... He said contrary to many believes that biotechnology or GM products are bad to humanity, "Biotechnology... (allAfrica.com)

    Nigeria: 'U.S. Suit Confirms GM Rice Contamination in The Country'  Nov 12, 2009
    Reacting to the development, ERA/FoEN said the US litigation showed the extent the biotechnology industry and its allies will go to "undermine food supplies" to unsuspecting consumers especially in Africa where there are weak biosafety laws. Relevant Links. (allAfrica.com)

    PolyMedix announces public offering  Nov 12, 2009
    Biotechnology company Inc. on Wednesday announced a public equity offering of up to $21 million. Radnor, Pa. (Philadelphia Business Journal, PA)

    Weather sideswipes Rudd in India visit  Nov 12, 2009
    Today he will visit India's Energy Research Institute and its biotechnology laboratories and give $50 million over five years towards the Australia-India Strategic Research Fund, which supports 50 projects across such areas as renewable energy, medicine and agriculture. With an Australia inquiry pending into the 10-week oil and gas leak off the West Australian coast, Mr Rudd will today announce $400,000 towards a project that is trying to develop the use of bacteria to clean up oil spills in the... (Sydney Morning Herald -- World)

    Biota to buy two new drugs businesses  Nov 12, 2009
    Biotechnology company Biota will greatly expand its pipeline of potentially life-saving drugs after agreeing to buy two offshore life-sciences businesses. The company, which developed the anti-flu drug Relenza, also confirmed at its annual meeting this morning it had plenty of cash in the bank to deliver on a promised $20 million capital return to shareholders. (Sydney Morning Herald -- Business)

    You want pesticides with that?  Nov 12, 2009
    You want pesticides with that. I think of architects as a kind of pioneer species. (Sydney Morning Herald -- Opinion)

    Troubled Altus files for bankruptcy  Nov 12, 2009
    Waltham biotechnology company Altus Pharmaceuticals Inc., which told regulators in September it was starting the process of shutting down its operations, yesterday filed for bankruptcy protection. In its filing, under Chapter 7 of the US Bankruptcy Code, the seven-year-old company, which had found it difficult to raise cash during the economic downturn, listed both assets and debts of between $1 million and $10 million. (Boston Globe)

    ImmunoGen names board chairman  Nov 12, 2009
    a Waltham biotechnology company that develops targeted anticancer products, said Stephen C. McCluski has been named board chairman, replacing former chief executive Mitchel Sayare. Sayare continues on the board as a director; in addition, the company said in a press release Howard Pien was elected to its board at its annual meeting. (Boston Globe)

    Neurocrine shares plunge on FDA rejection  Nov 11, 2009
    Shares in plummeted to their lowest level in more than five years, illustrating the peril faced by small companies -- including dozens of Boston area biotechnology firms -- whose value rests on a single product that has not yet reached the market. The FDA turned down an application by the 14-year-old San Diego company and , the world's largest drug maker, to sell a 15 milligram extended-release version of the insomnia drug Indiplon. (Yahoo News -- Sleep and Sleep Disorders)

    Halozyme takes bigger loss on testing expenses  Nov 11, 2009
    SAN DIEGO Biotechnology company Halozyme Therapeutics Inc. reported a bigger third-quarter loss on Friday, as it started clinical trials of a fast-acting insulin during the period. Halozyme lost $13. (Yahoo News -- Pharmaceutical Industry News)

    Allon Therapeutics Releases Third Quarter Operating Results  Nov 11, 2009
    Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and schizophrenia-related cognitive impairment. (CCNMatthews Press Releases)

    Training Supervisor  Nov 11, 2009
    Employee Type: Full-Time Industry: Biotechnology Healthcare - Health Services Manages Others: No Job Type: Training Health Care Education: 2 Year Degree Experience: At least 1 year(s) Post Date: 10/22/2009 Contact Information Ref ID: 4154 Description. TRAINING SUPERVISOR. (Pensacola News Journal)

    Pfizer Inc. Plans To Vacate Its R & D Center In New London  Nov 11, 2009
    Paul Pescatello, president of CURE, the biotechnology industry's main advocacy group in Connecticut, called the Pfizer announcement "as good as it could have been," given the alternative scenarios, and said that he did not see the loss of the New London office as a major blow to the biotech industry in the state. "The same amount of research activity is going to go on after this as before," he said. (FOX61, CT)

    Sanofi-Aventis on hunt for Boston partners  Nov 11, 2009
    CAMBRIDGE - The top executive of French drug maker Sanofi- reached out to Boston-area researchers and biotechnology start-ups yesterday, offering partnerships for innovation that could range from investing in drugs to outright acquisitions. Speaking to about 200 guests at a Sanofi-Aventis research site here, director general Christopher A. Viehbacher, who is based in Paris, outlined a strategy that is becoming common at pharmaceutical giants whose own research and development efforts have... (Boston Globe)

    Outlook darkens on Mass. job picture in ’10  Nov 11, 2009
    Governor Deval Patrick, speaking at the State House, said his administration is working to boost the state s economy, focusing on promising sectors such as alternative energy, education, and life sciences, which includes biotechnology and other health-related sectors. But, he acknowledged, If you re out of a job or at risk of losing your job, you could care less about what the statistics say. (Boston Globe)

    Hepatitis B Does Not Increase Risk For Pancreatic Cancer  Nov 11, 2009
    5, 2005) Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) have again achieved a breakthrough in research on hepatitis. The researchers, connected to Ghent University, have. (Science Daily)

    Dangers Of Incapacitating Chemical Weapons And Widespread Misuse Of Riot Control Agents  Nov 10, 2009
    "Incapacitant research, if allowed to continue unchecked and in secret, may lead to even more dangerous developments. If the revolutionary advances in genomics, biotechnology and neuroscience are put to use by weapons designers then tomorrow's arsenals may well hold weapons that alter your thoughts and emotions, weaken your immune system, target your sight or leave you sterile.". Dangerous Ambiguities'also highlights the failure of the Chemical Weapons Convention (CWC) to adequately regulate... (Science Daily)

    Affymax 3Q loss narrows partnership payments  Nov 10, 2009
    Biotechnology company Affymax Inc. said Wednesday its third-quarter loss narrowed on a boost in payments from its partner Takeda Pharmaceutical on the anemia drug candidate Hematide. The company lost $18. (Yahoo News -- Pharmaceutical Industry News)

    Drug Candidate For Treating Spinal Muscular Atrophy Identified  Nov 10, 2009
    30, 2007) A new biotechnology company founded by University of Delaware researchers, is developing technologies for repairing genes that cause rare, hereditary diseases such as sickle cell anemia and spinal. . (Science Daily)

    Enzon sells specialty drug business for $300M  Nov 10, 2009
    In 2008, Enzon announced plans to spin off its biotechnology business into an independent company so it could focus on developing treatments for cancer. It canceled those plans in December due to the weak state of the financial markets. (Yahoo News -- Pharmaceutical Industry News)

    Nobel Laureate, man who discovered virus, gives Claflin address  Nov 10, 2009
    Dr. Omar Bagasra, Claflin biology professor and director of the campus-based South Carolina Center for Biotechnology, said Montagnier s visit to the university was a significant one. He said the university is collaborating on Montagnier s work with HIV DNA.. (Orangeburg Times and Democrat, SC)

    SPECIAL REPORT  Nov 10, 2009
    Monsanto, a leader in agricultural biotechnology, spends about $2 million a day on scientific research that aims to improve on Mother Nature, and is positioning itself as a key player in the fight against hunger. The Italian farmer and the U.S. multinational represent the two extremes in an increasingly acrimonious debate over the future of food. (AlertNet)

    UCSD discovery allows scientists for the first time to experimentally annotate genomes  Nov 10, 2009
    In a recent Nature Biotechnology paper, "The transcription unit architecture of the Escherichia coli genome," the researchers describe a four-step systems approach that integrates multiple genome-scale measurements on the basis of genetic information flow to identify the organizational elements and map them onto the genome sequence ... "There are several high throughput methods developed recently like deep sequencing and micro array systems that we used," said Byung-Kwan Cho, a project scientist... (EurekAlert!)

    High court ponders what can be patented  Nov 10, 2009
    In an amicus brief filed with the Supreme Court by a group of biotechnology organizations that includes the , the patent and licensing arm of the , the group argues that the current patent system promotes investment into research activities and commercialization of technologies. Upholding the Bilski decision would discourage such investment and innovation. (Milwaukee Business Journal, WI)

    Stimulus funds aid MCG research  Nov 10, 2009
    Dr. McIndoe, the associate director of the Center for Biotechnology and Genomic Medicine at MCG, runs a coordinating bioinformatics unit that helps two consortiums through the National Institute of Diabetes and Digestive and Kidney Diseases. Part of his grant will pay for his work on an effort by the institute to bring together disparate data collections and ensure researchers have easier access to it. (The Augusta Chronicle)

    Leipzig drives for former glory days  Nov 10, 2009
    At least 60 employers have added jobs in Leipzig over the past decade, in cars, car parts, biotechnology and logistics. "Leipzig has advantages that other eastern cities can't match," said Volker Treier, the chief economist at the German Chamber of Commerce and Industry in Berlin. (Business Report, South Africa)

    Amylin signs weight-loss drug deal with Takeda  Nov 10, 2009
    The Amylin-Takeda deal comes amid a surge in obesity treatment research and development from the biotechnology industry. Several companies already have their potential drugs in late-stage development, setting the stage for a competitive market if each gains Food and Drug Administration approval. (Yahoo News -- Pharmaceutical Industry News)

    Opko Health narrows losses, reduces costs  Nov 10, 2009
    The Miami-based biotechnology development company (AMEX: OPK) reported a net loss of $6. 5 million, or 3 cents a share, on revenue of $1. (South Florida Business Journal, FL)

    CPO futures can hit RM2,625 per tonne  Nov 10, 2009
    Earlier in the first plenary session, MPOB director-general Datuk Dr Mohd Basri Wahid announced that the board had completed the sequencing of three oil palm genomes from two oil palm species via a consortium co-led by the MPOB Advanced Biotechnology and Breeding Centre and the US-based Orion Genomes. Tan Sri Bernard Dompok (second from left) visiting the expo at PIPOC 2009. (The Star Online, Malaysia -- Business)

    Woburn’s BioVex raises $30m more for cancer drug development  Nov 10, 2009
    BioVex Inc., a Woburn biotechnology company that raised $40 million in venture capital in March to develop a novel cancer-fighting treatment, today will disclose it has raised another $30 million. The funding rounds together represent the second-largest venture investment in a US biotechnology company this year, according to data from the National Venture Capital Association ... Astley-Sparke, who has a background in science and finance, moved the company to the Boston area in 2005 to be closer... (Boston Globe)

    EXAMPLES:  Engagement looks different at every institution  Nov 9, 2009
    Two years ago, it established a biotechnology initiative enabling students to work side by side in a lab with faculty. Because local community colleges offer several related programs, the new program also helped the school boost its transfer population. (USA Today)

    Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration  Nov 9, 2009
    Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. (Primezone Releases)

    Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL  Nov 9, 2009
    Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. (Primezone Releases)

    Five-step check for nano safety  Nov 9, 2009
    The group of experts says that if the global research community can take advantage of the safety infrastructure already in place for biotechnology and computing, then nanotechnology has a rosy future. But Dr Maynard, from the Woodrow Wilson International Center for Scholars in Washington DC, and colleagues say that the way science is carried out means it is ill-equipped to address novel risks from emerging technologies. (Yahoo News -- Nanotechnology)

    Novel Cancer Detection Method Uses Tiny Silica Beads To Adhere To Cells  Nov 9, 2009
    8, 2009) A novel method of detection of cervical cancer cells has been developed by Clarkson University Professor Igor Sokolov's group, an affiliate of the University's Nanoengineering and Biotechnology Laboratories Center (NABLAB). See also. (Science Daily)

    Mouse cloned to cure Parkinson's  Nov 9, 2009
    The embryonic "stem cells", reports the journal Nature Biotechnology, were grown into new tissue which was implanted into the mouse brain. However, many obstacles stand in the way of human treatments, say experts. (Yahoo News -- Parkinson's Disease)

    Supreme Court to decide: What kind of innovations get a patent?  Nov 9, 2009
    It has attracted 67 friend-of-the-court briefs from lawyers, scholars, and businesses, including Microsoft, the Biotechnology Industry Organization, Bank of America, Google, Yahoo, and L.L. Bean ... According to the group, Georgia Biomedical Partnership, the Federal Circuit's decision is already being applied to strike down protections to a broad class of biotechnology and medical inventions ... "Without the limited monopoly provided by patent protection, the biotechnology and pharmaceutical... (Christian Science Monitor -- World)

    A Math Geek's Ride to the High Court in Landmark Patent Fight  Nov 9, 2009
    "It's inconceivable that the Court will ultimately issue an opinion that will restrict biotechnology patenting and most likely will not restrict software patenting, either," Mandel said. Asked whether his patent application was too ethereal to be eligible for a patent, Warsaw said the patent was legit but added, "I'm not an attorney. I have an MBA and a couple of engineering degrees. Some of the legal arguments are beyond me.". (Law.com)

    Kenya: Researcher Awarded for Efforts in Fighting Malaria  Nov 9, 2009
    "To shorten the amount of time it takes to safely develop new medicines and vaccines, we work with academic institutions, governments, and other pharmaceutical and biotechnology companies," GSK says in its website. Relevant Links. (allAfrica.com)

    Budding scientists compete at MIT for $100,000 prize  Nov 8, 2009
    Walsh, who has played on the Titleist Junior Golf Tour, hopes to own a biotechnology company someday. Joyce said she can t decide between science and writing, but is leaning toward becoming a pediatrician. (Boston Globe)

    Exelixis shares rise on 3Q results  Nov 8, 2009
    NEW YORK Shares of biotechnology company Exelixis Inc. rose Friday after the company narrowed its profit loss on a surge in revenue from partnerships with several large pharmaceutical companies. The stock rose 57 cents, or 10 percent, to $6. (Yahoo News -- Pharmaceutical Industry News)

    Stinkatron: chaos at the top  Nov 8, 2009
    It is used for research in areas as diverse as forensic science, biotechnology, drug design, toxicology, food technology, engineering and medical therapies. In 2001, John Brumby, then minister for innovation, got approval for the synchrotron to be built on land adjacent to Monash University, and secured its start-up costs of $221 million in state and federal funding. (Sydney Morning Herald -- Australia)

    J&J to slash 7,000 to 8,000 jobs  Nov 8, 2009
    In May, Jed to buy cancer drug developer Cougar Biotechnology for 970 million in cash. Like rival drugmakers, Jtruggling to refill its pipeline with new drugs to offset sales lost to generic competition and flagging revenue from older products, including some dogged by safety concerns. (Yahoo News -- Pharmaceutical Industry News)

    DNA molecules in moss open door to new biotechnology  Nov 7, 2009
    "This, in turn, may simplify basic and applied research and biotechnology involving plants.". . (EurekAlert!)

    Frontiers of the future: In-gene-ous modifications  Nov 7, 2009
    Genetic engineering - inserting new genetic sequences into viruses, bacteria, plants and other animals - has seen a worldwide explosion of biotechnology. On the one hand, human genes are studied to locate abnormalities, which cause disorders or make an individual more susceptible to various diseases. (India Times, India -- Health/Science)

    ZymoGenetics: restraining orders lifted  Nov 7, 2009
    The Seattle biotechnology company (NASDAQ: ZGEN) on Wednesday disclosed that it had been slapped with the restraining orders as part of a lawsuit filed by four companies, including rival The lawsuit accuses ZymoGenetics of unfair competition, false advertising, trademark infringement and related claims, ZymoGenetics said. In a filing Friday with the , ZymoGenetics said the judge in Tennessee had vacated the restraining orders, which "have no further force or effect." The company did not... (Puget Sound Business Journal, WA)

    * Lee Kai-fu predicts happy future for Web teamwork  Nov 7, 2009
    The six emerging industries X tourism, health care, biotechnology, green energy, cultural and creative industries and high-end agriculture X are expected to generate a production value of NT$1 trillion (US$30. 7 billion) and 610,000 jobs by 2012, Chu said. (Taipei Times, Taiwan -- World)

    Novella Clinical  Nov 7, 2009
    Describe your business: Clinical research organization for biotechnology and pharmaceutical clients. Year founded: 1998. (Triangle Business Journal)

    * Private investment expected to grow by 2.62%: ministry  Nov 7, 2009
    5 billion, while biotechnology companies are expected to increase investment by 20 percent to NT$30 billion. Investment from the cultural and creative industry will increase 6 percent next year to NT$21. (Taipei Times, Taiwan -- World)

    Local biotech firm wins OK on cancer drug  Nov 7, 2009
    Gloucester Pharmaceuticals, a six-year-old Cambridge biotechnology start-up, has won approval from the Food and Drug Administration to market its first drug in the United States. The drug, called Istodax, treats a rare skin cancer known as cutaneous T-cell lymphoma, or CTCL. Roughly 20,000 people in the United States have the cancer, which affects the immune system. (Boston Globe)

    Lexington High School team rising to bird flu challenge  Nov 7, 2009
    Andrew is a senior who would like to become the president and chief executive officer of a biotechnology company. He is currently a member of the National Honor Society, has won two gold medals on the National Latin Exam, and is recognized as an AP Scholar with Honor. (Lexington Minuteman, MA)

    Threshold Pharmaceuticals 3Q loss widens on costs  Nov 7, 2009
    Threshold Pharmaceuticals Inc., a development-stage biotechnology company, said late Thursday its third-quarter loss widened on higher research, development, and interest expenses. The company lost $6. (Yahoo News -- Pharmaceutical Industry News)

    Halozyme takes bigger loss on testing expenses  Nov 7, 2009
    SAN DIEGO Biotechnology company Halozyme Therapeutics Inc. reported a bigger third-quarter loss on Friday, as it started clinical trials of a fast-acting insulin during the period. Halozyme lost $13. (Yahoo News -- Pharmaceutical Industry News)

    New Technique For Specifying Location Of Sugars On Proteins Paves Way For Medical Discoveries  Nov 7, 2009
    23, 2006) Investigators at Dartmouth's Thayer School of Engineering, the Dartmouth-Hitchcock Medical Center, and the biotechnology firm GlycoFi, Inc., report a breakthrough in using yeast to produce antibodies. (June 27, 2008) Researchers have succeeded in further unraveling and manipulating the glycosylation of proteins in plants. (Science Daily)

    New use found for old Valley gas field  Nov 7, 2009
    Meanwhile, a Palo Alto-based biotechnology company and two Visalia-based dairy technology companies also announced plans Monday to build a separate facility that would generate energy from dairy waste to power a new ethanol plant in the San Joaquin Valley. The news of the first operation from David Albers, who has a dairy in Fresno County, came in Tulare on the grounds of the World Ag Expo, which begins its three-day run today. (Fresno Bee -- Local)

    Farmers growing genetically engineereed corn break rules  Nov 6, 2009
    The new compliance information comes from reports produced by the companies that sell genetically engineered corn seed, and if anything they may understate the problem, says Gregory Jaffe, director of the biotechnology project with the Center for Science in the Public Interest (CSPI) ... He is the chair of the the industry's Agricultural Biotechnology Stewardship Technical Committee, which is responsible for coordinating the compliance assurance program. (USA Today -- Tech)

    Biotech firm opens pharmaceutical lab at Phoenix site  Nov 6, 2009
    A Los Angeles-based biotechnology company on Wednesday unveiled a $70 million Phoenix manufacturing site that will create up to 200 technology jobs. Abraxis Biosciences built the lab, at the site formerly owned by Watson Pharmaceuticals on 51st Avenue, to serve as the firm's manufacturing site for its pipeline of pharmaceuticals. (AZCentral -- Business)

    South Africa: GM Potato Gets Roasting  Nov 6, 2009
    Ben Pieterse, research and development manager, said: "We support biotechnology and the future benefits it can bring. We will, however, not support any products that can cause health risks". Relevant Links. (allAfrica.com)

    Human Bacterial Diversity Is Personalized  Nov 6, 2009
    Knight, also a faculty member in CU-Boulder's computer science department and who is a member of the university's Colorado Initiative in Molecular Biotechnology, said understanding the variation in human microbial communities holds promise for future clinical research. "If we can better understand this variation, we may be able to begin searching for genetic biomarkers for disease," he said. (Science Daily)

    Coughlin: Medfield, area towns must work to attract biotech  Nov 6, 2009
    Biotech firms would bring good, clean, high-paying jobs to the Neponset Valley, but the region s towns need to make it easier for businesses to come here, Massachusetts Biotechnology Council President Robert Coughlin told a gathering of municipal officials and industry representatives this week ... He spoke at a panel discussion Wednesday, Nov. 4 on biotechnology in the Neponset Valley, held at Norwood s Four Points by Sheraton, that brought together biotech reps, commercial brokers, developers,... (Medfield Press, MA)

    Newly revised guidelines for managing thyroid cancer published in Thyroid journal  Nov 6, 2009
    Its biotechnology trade magazine, Genetic Engineering chnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at. (EurekAlert!)

    Hopes fly for base land transfer in Weymouth  Nov 6, 2009
    The redevelopment plan for the base, now called SouthField, includes the construction of 2,855 homes, a movie studio production firm, a hotel, an 18-hole golf course, a conference center, boutique shops, restaurants, hiking baths, walkways, recreational fields, and a two million square foot commercial complex to accommodate a pharmaceutical company or biotechnology firm. LNR Property Corp. plans to construct these amenities over a 14-year period. (Weymouth News, MA)

    Gene Discovery Gives Clues to Crohn's Disease, Colitis  Nov 6, 2009
    The study is not the first to link interleukin-10 with IBD, noted study researcher Alejandro A. Schaffer, a staff scientist at the U.S. National Center for Biotechnology Information ... D., staff scientist, U.S. National Center for Biotechnology Information, Bethesda, Md. (MEDLINEplus)

    Trubion loses $6.2 million in Q3  Nov 6, 2009
    The Seattle biotechnology company (NASDAQ: TRBN), which is developing drugs for treating autoimmune and inflammatory diseases and cancer, said Q3 revenue increased to $4. 5 million, from $3. (Puget Sound Business Journal, WA)

    ZymoGenetics narrows loss, revenue up  Nov 6, 2009
    The Seattle biotechnology company (NASDAQ: ZGEN) said third-quarter revenue increased 131 percent, to $8. 5 million, from the year-ago quarter, due to sales of its bleeding-control drug Recothrom. (Puget Sound Business Journal, WA)

    Targeted Genetics sheds some office space  Nov 6, 2009
    The Seattle-based biotechnology company (NASDAQ: TGEN) said it continues to maintain offices in an adjacent building on Olive Way in Seattle, though it didn't specify the square footage of that space. Targeted Genetics said in early October that the NASDAQ stock exchange had given it until early next year to meet two minimum exchange listing requirements or face delisting. (Puget Sound Business Journal, WA)

    Amylin signs weight-loss drug deal with Takeda  Nov 6, 2009
    The Amylin-Takeda deal comes amid a surge in obesity treatment research and development from the biotechnology industry. Several companies already have their potential drugs in late-stage development, setting the stage for a competitive market if each gains Food and Drug Administration approval. (Yahoo News -- Pharmaceutical Industry News)

    Company to grow in Cambridge  Nov 5, 2009
    He said the United States should focus economic leadership in four areas: information technology, biotechnology, clean technology, and advanced manufacturing, such as nanotech, electronics, and batteries. D.C. Denison can be reached at. (Boston Globe)

    Mouse cloned to cure Parkinson's  Nov 5, 2009
    The embryonic "stem cells", reports the journal Nature Biotechnology, were grown into new tissue which was implanted into the mouse brain. However, many obstacles stand in the way of human treatments, say experts. (Yahoo News -- Parkinson's Disease)

    Monsanto opens research center in China  Nov 5, 2009
    The Monsanto Biotechnology Research Center in Zhongguancun, Beijing, will participate in early-stage bioinformatics and genomics research, and serve as a base for collaborations with Chinese scientists, the company said. John McLean is general manager of the center. (St. Louis Business Journal, MO)

    Latest News: Biotechnology

    Back to Biology News

[ Terms Of Use | Privacy | About ]
©1998-2009 SurfWax, Inc.
All rights reserved. Patents pending.



Copyright SurfWax, Inc. 2009